A U.S. Food and Drug Administration (FDA) advisory panel narrowly recommended approval of four previously unapproved peptides: BPC-157, KPV, TB-500, and MOTS-c.
A U.S. Food and Drug Administration (FDA) advisory panel narrowly recommended allowing pharmacies to dispense four unapproved peptide drugs: Bpc-157, Kpv, Tb-500, and Mots-c.
This decision advances an initiative launched by Secretary of Health Robert F. Kennedy Jr. to bring widely used but legally controversial compounds into the regulated market. Despite opposition from leading FDA scientists, who argued that there was a lack of evidence to evaluate the safety and effectiveness of these compounds, the vote was successful.
The 14-member Pharmaceutical Product Development Advisory Committee approved the formulation of Bpc-157, Kpv, and Tb-500 by a vote of 8-6, with 1 abstention; while Mots-c, which is currently being evaluated for the treatment of obesity and osteoporosis, was approved by a vote of 7-5, with 2 abstentions. 1 These voting results do not mean that these peptide drugs have received FDA approval, but rather recommend that these compounds be added to the list of substances that pharmacies can manufacture for patients with a prescription. 1
Despite this decision, the FDA is not required to follow the panel’s recommendations, and any changes will require a formal rulemaking process. 1 The committee currently plans to meet again on July 24 to vote on three other peptide drugs: emidetide, ipilon, and Semaxis. 1
”It’s important to understand that the marketplace is conflating three separate legal events: descheduling of Class II drugs, a recommendation from the Prescription Drug Advisory Committee (PCAC), and formal rescheduling of Class I drugs following public comment and consultation. The PCAC recommendation still initiates the formal rulemaking process, which typically takes eight to twelve months before 503A pharmacies receive clear legal approval to dispense these drugs. The current direction is the right one. But stakeholders need to clearly understand their position and make informed decisions accordingly,” said Dustin Robinson, founding partner, CPA, and attorney at the law firm LumaLex.
”I voted for something, but I don’t know what exactly. It’s like a black box to me.”
Eight of the 14 committee members were recently appointed by Kennedy, a composition that has drawn sharp criticism. 2 According to Reuters, six of the 14 new appointees work at or manage clinics that provide peptide therapies, and several of them could directly benefit if these compounds were cleared for wider use. 2 One of the committee members, Tennessee Senator Bobby Hashbugh, is the son of Tennessee Republican Representative Diana Hashbugh. Diana Hashbugh wrote to Kennedy last year asking for permission for staff working on peptide drug development to manufacture certain drugs. 1
Paul Knopfler, a professor of cell biology at the University of California, Davis, questioned the panel’s fundamental impartiality, saying, “Many of the members who voted in favor would benefit from allowing Bpc-157 to be used in combination therapies. How can that be acceptable?”
The US Department of Health and Human Services defended this process. Department of Health and Human Services spokesperson Emily Hilliard stated, “All committee members underwent the same ethics and compliance review process as all FDA advisory committee members.” She added that candidates who did not meet existing ethical requirements were excluded.
FDA officials have reportedly repeatedly encountered a fundamental problem: the chemical nature of these peptides remains poorly understood. Unlike traditional drugs, there is no generally accepted chemical formula for each compound, making it extremely difficult to assess their potential uses.
”We’ve never been faced with a question like, ‘What is this, really?’” FDA spokesman Russell Wesdick said at a panel meeting Thursday morning.
The agency reviewed these peptide drugs for specific indications, including Bpc-157 for the treatment of ulcerative colitis, Kpv for accelerating wound healing and treating inflammatory diseases, Tb-500 for accelerating wound healing, and Mots-c for the treatment of obesity and osteoporosis .
The panel of experts who voted for the bill often echoed the Kennedy administration’s rhetoric, viewing access to medications as a matter of patient safety. Dr. Halim Mohammed, chief medical officer at Gameday Men’s Health, a Florida clinic offering peptide medications, also voted in favor of Bpc-157 on this basis. “As a physician, I must ensure patient safety to the greatest extent possible.”
Dr. Gabriel Alizaidi, a clinical researcher at Maximus, an online clinic offering peptide medications, said he voted in favor despite being “frankly very disappointed” with the Bpc-157 data. David Pope, chief pharmacist at Xifin Pharmacy Solutions in Georgia, said he voted to “return decision-making power to patients, doctors, and pharmacists.”¹
The expert panel that voted against the FDA’s recommendations consisted primarily of physicians and patient advocacy groups. Dr. Brian Lee, an associate professor of medicine at the Keck School of Medicine of the University of Southern California, voted against the recommendations, arguing that the panel’s support could be misinterpreted by the public as an FDA endorsement of the treatment’s effectiveness. “In terms of effectiveness, we know that 30% of patients taking a placebo report improvement based on their own reports or even objective data,” Dr. Lee said.
Josh Mehlman, chairman of the board of directors of the Neuroendocrine Tumor Research Foundation, voted against KPV. “I’m here to vote, but I don’t know what it is,” he said. “It’s like a black box to me.”¹
The Pharmaceutical Executive Newsletter offers unique insights covering strategic analysis, leadership trends, and market information for decision makers in the biopharmaceutical industry.
Post time: Oct-20-2026